Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Digital clinical trials

- PMLiVE

Kate Shaw comments the appointment of an independent review on clinical trials in the UK.

The news comes after a report by the Association of the British Pharmaceutical Industry (ABPI) highlighted a 44% decline in industry clinical trials in the UK over the last five...

Innovative Trials

Patient Recruitment: Think Global, Act Local

Global clinical trials are a vital component of pharma R&D. Utilizing sites in multiple countries not only provides increased access to eligible and diverse patients - and therefore more robust...

Innovative Trials

- PMLiVE

UK government commissions independent review into clinical trials

The last five years have seen a 44% drop in commercial clinical trial recruitment in the UK

- PMLiVE

Paris Court of Appeal overturns Novartis and Roche’s €444m anti-competitiveness fine

It was questioned whether the companies had used their market power to boost sales of their eye disease drug

- PMLiVE

Novartis’ Cosentyx shows continued improvement in hidradenitis suppurativa patients

An estimated one in 100 people globally are affected by the inflammatory skin disease

PHARMACEUTICAL MARKETING STRATEGY FOR THE DIGITAL AGE

Pharmaceutical Marketing Strategies For The Digital Age

In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...

Genetic Digital

- PMLiVE

Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients

Kate Shaw, Innovative Trials' Founder & CEM, reflects on the exciting news for patients affected by cancer in the UK.

Innovative Trials

Virtual Tools for Promoting Diversity in Pharma and Clinical Trials

It is no secret that Pharma (still) has a major diversity problem.

Impetus Digital

- PMLiVE

Novartis receives EC approval for Pluvicto to treat adult cancer patients

Patients receiving Pluvicto plus best standard of care had a 38% reduction in the risk of death

- PMLiVE

Novartis’ iptacopan shows promise as rare blood disease treatment in phase 3 study

Around 82.3% of patients achieved haemoglobin-level increases of 2g/dL or more from baseline

- PMLiVE

Novartis partners with Cancer Research UK for rare cancer trial

The trial enrolled both paediatric and adult patients with any rare form of cancer

- PMLiVE

Novartis announces positive phase 3 results for prostate cancer drug Pluvicto

The study met its primary endpoint of radiographic progression-free survival

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links